Deep Dive: Page 9
Industry insights from our journalists
-
Liquid biopsies: The next frontier in cancer?
Money is flooding into the space as dozens of companies work to develop reliable tests for cancer from a simple blood draw.
Ned Pagliarulo • Feb. 13, 2017 -
How biomarkers cost Bristol-Myers the lung cancer market
A risk-averse approach to biomarkers opened the door for Merck's Keytruda to surpass Bristol-Myers' Opdivo in the highly important lung cancer market.
Lisa LaMotta • Feb. 13, 2017 -
Microbiome work reignites after Seres' initial flame-out
Despite a trial failure from the first public microbiome-focused company's lead product, market analysts say investment is still flowing and the field could show dramatic growth over time.
Judy Packer-Tursman • Feb. 10, 2017 -
Lilly turns to pain after solanezumab failure
With a new focus on pain and migraine medications, Eli Lilly hopes to reinvigorate its neuroscience pipeline and portfolio.
Jacob Bell • Jan. 25, 2017 -
7 companies to know in the emerging biosimilars field
Three more biosimilars won FDA approval last year and dozens more are moving through the pipeline. Here's some of the companies at the forefront of the growing drug class.
Ned Pagliarulo • Jan. 23, 2017 -
FDA
Biosimilars: What's in a name?
The FDA recently finalized naming conventions for biosimilars, putting in place an important piece of the regulatory framework for the copycat biologics.
Ned Pagliarulo • Jan. 23, 2017 -
Why Jay Bradner thinks Novartis can recharge drug discovery
Speaking with BioPharma Dive at J.P. Morgan, the head of NIBR explained the rationale behind recent restructuring and detailed the Swiss pharma's focus on immuno-oncology.
Ned Pagliarulo • Jan. 17, 2017 -
FDA
FDA to drugmakers: Don't let manufacturing lead to rejection
In a year when more drugs were rejected for GMP issues than in the past, the FDA's outgoing CDER director warned companies to ensure compliance.
Ned Pagliarulo • Jan. 5, 2017 -
Biotechs line up to tap growing ophthalmics market
As Restasis and Lucentis near the end of their patent lifecycles, new innovations are driving a booming pipeline in the space.
Jacob Bell • Dec. 21, 2016 -
Armed with IPO cash, CRISPR biotechs grow gene-editing tech
Even as a high-stakes patent battle steals headlines, the three CRISPR biotechs which IPO'd this year are busy building momentum.
Ned Pagliarulo • Dec. 12, 2016 -
Women in biotech: Out on the frontline
While there is still a steep gender discrepancy in the biopharma industry, smaller biotechs have embraced female leaders more readily. Some of the most closely watched companies have women at the helm.
Suzanne Elvidge • Dec. 12, 2016 -
The increasing threat of antimicrobial resistance
How the overuse of antibiotics has taken its toll on society and what drug developers are doing about it.
Suzanne Elvidge • Nov. 16, 2016 -
Advice to an emerging biotech
BioPharma Dive spoke to a number of biotechs about how incubators can help solve the problems faced in early drug development. Here's what they said.
Ned Pagliarulo • Nov. 7, 2016 -
5 trends turning biotech toward incubators
High real-estate costs. Scarce lab space. Access to capital. Incubators are ramping up support to help emerging biotechs avoid common pain points.
Ned Pagliarulo • Nov. 7, 2016 -
How incubators are accelerating early drug development
Pharma has struggled to find innovation, and academics have a poor track record moving compounds forward. Now other players are bridging the gap.
Lisa LaMotta • Nov. 7, 2016 -
How pharma is using Twitter to connect with patients
Big pharma has a lot of constraints when it comes to social media, but their Twitter feeds can be very useful ... sometimes.
Lisa LaMotta • Oct. 26, 2016 -
Insulin makers become casualties of pricing war
Novo Nordisk, Sanofi and Eli Lilly are facing off in the insulin market, battling for position as prices go down and competition heats up.
Ned Pagliarulo • Oct. 13, 2016 -
Downfall of a unicorn: How Theranos fell apart
Elizabeth Holmes' decision to close down Theranos' clinical labs represents a marked retreat from her original aim to transform the blood-testing business.
Ned Pagliarulo • Oct. 10, 2016 -
Biosimilars emerge in US, but what to call them?
With four biosimilars now approved in the U.S., the competitive threat for biologics is apparent. What's not clear? How to name them.
Ned Pagliarulo • Oct. 3, 2016 -
FDA
Drama at FDA: 5 things to know about the Sarepta approval
Summary review documents released by the agency reveal the high-stakes decision sparked fierce debate among FDA leadership.
Ned Pagliarulo and Lisa LaMotta • Sept. 19, 2016 -
Pharma plays the blame game at the top
The biopharma industry has seen plenty of changes this year with seven CEO departures at major firms.
Lisa LaMotta • Sept. 8, 2016 -
How Mylan ended up with an EpiPen monopoly
A strong marketing program and some old-fashioned good luck made EpiPen Mylan's first $1 billion product.
Lisa LaMotta • Aug. 24, 2016 -
MI Labs to biotechs: Call us home
Founded last year, Mass Innovation Labs styles itself as a “chief operating officer” for emerging companies.
Ned Pagliarulo • Aug. 16, 2016 -
Seizing CAR-T lead, Kite readies commercial-scale manufacturing
Along with safety, the ability to quickly manufacture the first wave of CAR-T therapies will likely be a key test of commercial viability.
Ned Pagliarulo • Aug. 9, 2016 -
Why Allergan thinks an 'open science' approach can help it develop new antibiotics
BioPharma Dive spoke with David Nicholson, head of R&D at Allergan, about his company’s continued efforts to develop novel antibiotics, even as other companies have dropped out of R&D.
Ned Pagliarulo • July 14, 2016
Previous
